Amedisys price target raised to $125 from $103 at Oppenheimer. Oppenheimer analyst Michael maintained an Outperform rating on Amedisys and raised his price target to $125 from $103, telling investors in a research note that he remains a buyer following meetings with management. The company is hopeful that CMS will either change or be force to change the 6.2% behavioral adjustment, Wiederhorn says, adding that Amedisys is particularly bullish on the outlook for the hospice business, which now accounts for 45% of EBITDA.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.